CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma: In patients with cutaneous T cell lymphoma, mogamulizumab, a defucosylated anti-CCR4 antibody, reduced the levels of CCR4+ Tregs and showed significant efficacy [169].